Value-Based Pricing and State Reform of Prescription Drug Costs

JAMA. 2017 Aug 15;318(7):609-610. doi: 10.1001/jama.2017.8255.

Authors

Thomas J Hwang¹, Aaron S Kesselheim¹, Ameet Sarpatwari¹

Affiliation

¹ Program on Regulation, Therapeutics, and Law, Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.

PMID: 28692713
DOI: 10.1001/jama.2017.8255

No abstract available

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Costs and Cost Analysis
Drug Costs / legislation & jurisprudence*
Drug Costs / trends
Health Policy
Insurance, Pharmaceutical Services / economics
Insurance, Pharmaceutical Services / legislation & jurisprudence*
Medicaid / economics*
Medicaid / legislation & jurisprudence
New York
Prescription Drugs / economics*
State Health Plans*
United States
Value-Based Health Insurance

Substances

Prescription Drugs